Answer
Prolia (denosumab) treats osteoporosis in postmenopausal women and men at increased fracture risk, bone loss associated with hormone ablation in men with prostate cancer at increased fracture risk, and bone loss associated with long-term systemic glucocorticoid therapy in adults at increased fracture risk.
Sources for this answer
- Prolia 60 mg solution for injection in pre-filled syringeAmgen Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 37Document updated
Sources checked